Prosecution Insights
Last updated: September 15, 2026
Application No. 18/068,077

ANALYTE SENSORS AND SENSING METHODS FEATURING DUAL DETECTION OF GLUCOSE AND KETONES

Non-Final OA §112
Filed
Dec 19, 2022
Priority
Jan 28, 2019 — provisional 62/797,566 +2 more
Examiner
ROBERTS, ANNA L
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Abbott Laboratories
OA Round
4 (Non-Final)
56%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
91 granted / 162 resolved
-13.8% vs TC avg
Strong +38% interview lift
Without
With
+37.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
55 currently pending
Career history
212
Total Applications
across all art units

Statute-Specific Performance

§101
16.0%
-24.0% vs TC avg
§103
39.3%
-0.7% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 162 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 20 August 2026 has been entered. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 48 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 48 recites the limitation “exposing the analyte sensor of claim 51 to interstitial fluid” in line 3 of the claim. It is unclear if “interstitial fluid” is meant to refer to the user’s interstitial fluid, as introduced in claim 51, or if it may refer to a different interstitial fluid. The limitation is interpreted as referring to the user’s interstitial fluid and it is recommended that the claim be amended to “exposing the analyte sensor of claim 51 to the user’s interstitial fluid” or “exposing the analyte sensor of claim 51 to the interstitial fluid”. Allowable Subject Matter Claims 5, 46-4 allowed. Claim 48 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. The following is an examiner’s statement of reasons for allowance: The prior art of the record fails to teach and/or fairly suggest, in combination with all other recited limitations, “a ketones-responsive active area for detecting ketones, the ketones-responsive active area disposed directly upon a surface of the first working electrode, the ketones-responsive active area comprising a first polymer and a cofactor” of claim 51. The most pertinent prior art of the record, McColl (WO 2011030093—previously cited) fails to teach the above limitation, wherein the ketones-responsive active area has been clarified to be disposed directly upon the surface of the first working electrode, as argued by the applicant in page 12 of the remarks dated 06 August 2025 as an interpretation of McColl which includes the cofactor in the ketones-responsive active area would not be disposed directly upon the surface of the first working electrode, nor does McColl adequately suggest making this modification. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANNA ROBERTS whose telephone number is (571)272-7912. The examiner can normally be reached M-F 8:30-4:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alexander Valvis can be reached at (571) 272-4233. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANNA ROBERTS/Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Show 4 earlier events
Jul 25, 2025
Notice of Allowance
Feb 24, 2026
Request for Continued Examination
Feb 25, 2026
Response after Non-Final Action
Mar 10, 2026
Non-Final Rejection mailed — §112
Apr 08, 2026
Response Filed
Aug 20, 2026
Request for Continued Examination
Aug 21, 2026
Response after Non-Final Action
Sep 01, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12672825
DEVICES, SYSTEMS AND METHODS OF PELVIC FLOOR MUSCLE EXAMINATION
4y 0m to grant Granted Jul 07, 2026
Patent 12672826
USING A HEARABLE TO GENERATE A USER HEALTH INDICATOR BASED ON USER TEMPERATURE
3y 7m to grant Granted Jul 07, 2026
Patent 12667291
UROFLOWMETER
2y 4m to grant Granted Jun 30, 2026
Patent 12608083
WEARABLE DEVICE FOR PROVIDING HAPTIC FEEDBACK AND OPERATION METHOD THEREOF
4y 0m to grant Granted Apr 21, 2026
Patent 12605094
CLOSED TYPE ARTERIAL BLOOD COLLECTION APPARATUS
2y 9m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
56%
Grant Probability
94%
With Interview (+37.9%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 162 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month